SK
About SK
SK Biopharmaceuticals is a global pharmaceutical company dedicated to the research, development, and commercialization of innovative treatments, primarily focusing on central nervous system (CNS) disorders and oncology. Originating from SK Group in 1993 and spun off in 2011 to concentrate on CNS, the company has achieved significant milestones, including being the first Korean firm to independently discover, develop, and commercialize a molecule from inception through FDA approval, exemplified by its epilepsy treatment, cenobamate (U.S. brand name: XCOPRI®). They also have another FDA-approved medication, solriamfetol, for sleep disorders.
Beyond its established CNS portfolio, SK Biopharmaceuticals is strategically expanding into oncology, leveraging advanced platforms such as targeted protein degradation (TPD) and radiopharmaceutical therapy (RPT). The company is actively integrating artificial intelligence (AI) across its operations to enhance drug discovery, accelerate clinical development, and improve patient care. A notable initiative in this area is the 2025 launch of Mentis Care, a joint venture with Eurofarma, aimed at developing an AI-driven integrated epilepsy management platform. Their pipeline includes therapies for conditions such as epilepsy, Lennox-Gastaut syndrome, rare neurological diseases, schizophrenia, bipolar disorder, attention deficit/hyperactivity disorder, and various advanced solid tumors.
For physicians, SK Biopharmaceuticals’ commitment to innovation means a continuous effort to address high unmet medical needs through both novel drug development and the application of cutting-edge technologies like AI to optimize therapeutic outcomes and patient support systems.
What Physicians Need to Know
For physicians, SK Biopharmaceuticals' AI tools, particularly the Mentis Care platform, offer significant advantages in managing epilepsy. The AI-powered system provides real-time seizure detection and prediction, delivering crucial notifications to patients, caregivers, and healthcare professionals, enabling more proactive and timely interventions. The integrated web service grants real-time access to comprehensive patient data, including seizure history, statistics, and medication adherence, facilitating more organized and informed patient care. The platform's focus on collecting real-world data and its potential for personalized services, along with its ability to support post-marketing surveillance for anti-seizure medications like cenobamate, can lead to more tailored and effective treatment strategies. Furthermore, the ongoing joint research with institutions like Emory University aims to develop versatile AI models applicable across various monitoring devices, promising continuous and real-life environment-based monitoring.
SK Biopharmaceuticals has established a key strategic integration through its joint venture, Mentis Care, with Eurofarma for the global commercialization of its AI-based epilepsy management platform. This partnership leverages Eurofarma's market reach and digital expertise. Additionally, the company collaborates with PhnyX Lab to integrate generative AI into its drug development pipeline and with Emory University School of Medicine for advanced AI model development in seizure detection and prediction.
What the Web Says
SK Biopharmaceuticals, a South Korean pharmaceutical company, has recently launched a joint venture with Eurofarma to develop an AI-based epilepsy management platform. While specific product reviews for this new platform are not yet widely available, general sentiment towards SK Biopharmaceuticals as an employer appears to be mixed, with some employees praising its work environment and others expressing concerns about management and compensation.
Overall: MixedStrengths
- Innovative approach with AI-based epilepsy management platform
- Potential for global market expansion through joint ventures
- Focus on neurological disorders, addressing unmet medical needs
- Opportunities for career growth in a developing company (based on some employee reviews)
- Good work-life balance reported by some employees
- Strong research and development capabilities
Limitations
- Lack of readily available product reviews for the new AI platform
- Mixed employee reviews regarding management and compensation
- Potential for long working hours in some departments
- Communication issues reported by some employees
- Limited information on specific company culture aspects from public reviews
- Competition in the pharmaceutical and AI healthcare sectors
Based on reviews from: Biospace, Glassdoor, Reddit, Unknown healthcare IT reviewers (due to lack of specific mentions for SK Biopharmaceuticals' new platform)
Last updated: 2026-07-20
Videos
News, demos, and interviews about SK.
Videos load interactively. If none appear, search YouTube for SK →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]